Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism

Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism

Insulin resistance and diabetes are both associated with chronic hepatitis C virus (HCV) infection, and the glucagon-like peptide-1(GLP-1) receptor agonist, liraglutide, is a common therapy for diabetes. Our aim was to investigate whether liraglutide treatment can inhibit HCV replication. A cell cul...

Full description

Bibliographic Details
Main Authors:	Mei-Yueh Lee, Wei-Chun Chen, Wei-Hao Hsu, Szu-Chia Chen, Jin-Ching Lee
Format:	Article
Language:	English
Published:	MDPI AG 2019-09-01
Series:	International Journal of Molecular Sciences
Subjects:	hepatitis C virus liraglutide GLP-1 diabetes mellitus AMPK
Online Access:	https://www.mdpi.com/1422-0067/20/18/4569

Similar Items

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

LIRAGLUTIDE: SUCESSO NO TRATAMENTO DO DIABETES MELLITUS EM MONOTERAPIA E ASSOCIAÇÕES – REVISÃO SISTEMÁTICA
by: George Robson Ibiapina, et al.
Published: (2011-12-01)

Efficacy and safety of liraglutide in Indian adolescents with obesity
by: I. S. Kochar, et al.
Published: (2019-06-01)

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
by: Louise Vedtofte, et al.
Published: (2020-10-01)

The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway
by: Yi Bao, et al.
Published: (2015-07-01)

Continuation of Liraglutide during Fasting is not Associated with Hypoglycaemia
by: Rosalie Koot, et al.
Published: (2017-10-01)

Clinical Impact of Liraglutide as a Treatment of Obesity
by: Alruwaili H, et al.
Published: (2021-03-01)

The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy
by: Yini He, et al.
Published: (2020-01-01)

Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus
by: Mala Dharmalingam, et al.
Published: (2011-01-01)

Complex vasoactivity of liraglutide. Contribution of three gasotransmitters
by: Eszter Sélley, et al.
Published: (2015-05-01)

The Discovery and Development of Liraglutide and Semaglutide
by: Lotte Bjerre Knudsen, et al.
Published: (2019-04-01)

Effects of liraglutide on obesity-associated functional hypogonadism in men
by: M Jensterle, et al.
Published: (2019-02-01)

Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R
by: Ziyi Li, et al.
Published: (2020-10-01)

Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
by: Xu Zhao, et al.
Published: (2019-01-01)

Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs
by: Åke Sjöholm
Published: (2010-03-01)

Liraglutide exhibits anti-inflammatory activity through the activation of the PKA/CREB pathway
by: Li Wang, et al.
Published: (2019-10-01)

Glucagon-like peptide-1 analogue, liraglutide, delays onset and reduces severity of experimental autoimmune encephalitis in Lewis rats
by: Brian DellaValle, et al.
Published: (2016-11-01)

Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
by: Ying Liu, et al.
Published: (2017-12-01)

A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
by: Mariana Cornelia Tilinca, et al.
Published: (2021-06-01)

Growth differentiation factor‐15, treatment with liraglutide, and clinical outcomes among patients with heart failure
by: Abhinav Sharma, et al.
Published: (2021-08-01)

Liraglutids viktminskningseffekt
by: Hazime, Zahraa
Published: (2020)

Liraglutide Activates Glucagon-Like Peptide 1 Receptor to Attenuate Hyperglycemia through Endogenous Beta-Endorphin in Diabetic Rats
by: Kai-Chun Cheng, et al.
Published: (2020-11-01)

The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis
by: Qihong Que, et al.
Published: (2019-06-01)

The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study
by: Christina Bording Rasmussen, et al.
Published: (2014-08-01)

Glucagon-like peptide-1 (GLP-1) and liraglutide, a synthetic GLP-1 analog, inhibit inflammation in human aortic endothelial cells via calcium and AMPK dependent mechanisms
by: Krasner, Nadia Marie
Published: (2016)

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
by: Maurice B. Bizino, et al.
Published: (2019-04-01)

Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial
by: Natia Peradze, et al.
Published: (2019-10-01)

Liraglutide overdose: A case report and an updated review
by: Sharafaldeen Bin Nafisah, et al.
Published: (2020-01-01)

A Diabetic Patient Complicated With Pancreatic Cancer After Using Liraglutide: A Case Report
by: Shengjie Wu, et al.
Published: (2021-01-01)

A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients
by: Huub J. van Eyk, et al.
Published: (2019-07-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Neff LM
Published: (2010-07-01)

Liraglutide Protects Against Brain Amyloid-β<sub>1–42</sub> Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation
by: Ana I. Duarte, et al.
Published: (2020-03-01)

The Effects of Liraglutide on In Vitro Fertilization in Mice Following Experimental Diabetes
by: Rafieh Khalily, et al.
Published: (2020-03-01)

Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
by: Preman Kumarathurai, et al.
Published: (2021-01-01)

SCFAs-Induced GLP-1 Secretion Links the Regulation of Gut Microbiome on Hepatic Lipogenesis in Chickens
by: Jian-Mei Zhang, et al.
Published: (2019-09-01)

Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
by: Lyudmila Alexandrovna Ruyatkina, et al.
Published: (2017-06-01)

Efficacy of Liraglutide Application in Patients with Diabetes Mellitus Type 2 and Obesity in Real Clinical Practice (Literature Review the and Findings of Our Own Observations)
by: V.I. Pankiv
Published: (2014-09-01)

The Glp-1 Analog Liraglutide Protects Against Angiotensin II and Pressure Overload-Induced Cardiac Hypertrophy via PI3K/Akt1 and AMPKa Signaling
by: Ran Li, et al.
Published: (2019-06-01)

Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes
by: Savchenko Liudmyla G., et al.
Published: (2019-09-01)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
by: Fujishima Yuya, et al.
Published: (2012-09-01)